Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Stanford University.
Recruitment status was  Not yet recruiting
Celgene Corporation
Information provided by:
Stanford University Identifier:
First received: May 28, 2010
Last updated: NA
Last verified: May 2010
History: No changes posted

The purpose of this study is to determine the safety and efficacy of pomalidomide over a 12 week duration in the treatment of chronic cough in patients with IPF as measured by a Cough Symptom Diary, Visual Analogue Scale for Cough Severity, Leicester Cough Questionnaire, St. George Respiratory Questionnaire, Cough-Specific Quality-of-Life Questionnaire, and adverse event reporting. There will be an option open to participants, who respond to treatment by meeting pre-determined criteria, to remain in the study for an additional 9 months or for a total of 54 weeks

Condition Intervention Phase
Pulmonary Fibrosis
Drug: pomalidomide (CC-4047
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Outcome Measure: Cough related QOL as measured by Cough-Specific Quality of LIfe instrument (CQLQ) [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Outcome Measure: Cough severity as measured by Leicester Cough Questionnaire (LCQ), Visual Analog Scale (VAS), St. George Respiratory Questionnaire (SGRQ) [ Time Frame: 12 wks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: July 2010
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Understand and voluntarily sign an informed consent form.
  2. >18 and < 75 years old at the time of signing the informed consent form.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Have a diagnosis of Idiopathic Pulmonary Fibrosis in accordance to American Thoracic Society guidelines.
  5. Persistent cough:

    • as defined by a cough that adversely affects the patient's quality of life and has been present for at least 3 months.

  6. Laboratory test results within these ranges:

    • Absolute neutrophil count >2 x 103/ul
    • Platelet count >100,000 /mm³
    • Serum creatinine < 2.0 mg/dL
    • Total bilirubin < 1.5 mg/dL
  7. Diffusion capacity > 25%predicted
  8. Forced vital capacity <80% predicted • AST (SGOT) and ALT (SGPT) < 2 x ULN

8. Able to take aspirin (81 or 325 mg) daily as prophylactic anti-coagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  2. Females of child-bearing potential defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
  3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  4. Use of any other experimental drug or therapy within 28 days of baseline.
  5. Known hypersensitivity to thalidomide or lenalidomide.
  6. Any prior use of thalidomide, lenalidomide or pomalidomide (CC-4047).
  7. Known positive for HIV or infectious hepatitis, type A, B or C.
  8. History of deep venous thrombosis
  9. History of pulmonary embolism
  10. Use of the following anti-tussive agents must be discontinued 14 days prior to their baseline visit. -

1. prednisone 2. narcotic anti-tussives 3. baclofen 4. neurontin 11. Treatment for infection or acute exacerbation within past 3 months

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01135199

Contact: Susan S Jacobs, RN, MS (650) 725-8082

United States, California
Stanford University School of Medicine Not yet recruiting
Stanford, California, United States, 94305
Contact: Susan S Jacobs, RN, MS    650-725-8082   
Principal Investigator: Glenn D. Rosen         
Sub-Investigator: Paul K Mohabir         
Sub-Investigator: Julie Olsson         
Sponsors and Collaborators
Stanford University
Celgene Corporation
Principal Investigator: Glenn D. Rosen Stanford University
  More Information

Responsible Party: Glenn D. Rosen, Stanford University School of Medicine Identifier: NCT01135199     History of Changes
Other Study ID Numbers: SU-05302008-1189, Protocol # 15447
Study First Received: May 28, 2010
Last Updated: May 28, 2010
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 20, 2014